PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2874527-0 1986 Huntington"s disease: effect of cysteamine, a somatostatin-depleting agent. Cysteamine 32-42 somatostatin Homo sapiens 46-58 2289475-1 1990 The time-dependent pro- and anticonvulsant effects of cysteamine, a depletor of somatostatin, were investigated on the development and expression of amygdaloid kindled seizures. Cysteamine 54-64 somatostatin Homo sapiens 80-92 2289475-6 1990 Since it has been reported that somatostatin is released during generalized seizures, the seizures given 4 h after cysteamine may encourage the somatostatin depletion by cysteamine and thereby potentiate its later anticonvulsant effects. Cysteamine 115-125 somatostatin Homo sapiens 32-44 2289475-6 1990 Since it has been reported that somatostatin is released during generalized seizures, the seizures given 4 h after cysteamine may encourage the somatostatin depletion by cysteamine and thereby potentiate its later anticonvulsant effects. Cysteamine 115-125 somatostatin Homo sapiens 144-156 2289475-6 1990 Since it has been reported that somatostatin is released during generalized seizures, the seizures given 4 h after cysteamine may encourage the somatostatin depletion by cysteamine and thereby potentiate its later anticonvulsant effects. Cysteamine 170-180 somatostatin Homo sapiens 32-44 2289475-6 1990 Since it has been reported that somatostatin is released during generalized seizures, the seizures given 4 h after cysteamine may encourage the somatostatin depletion by cysteamine and thereby potentiate its later anticonvulsant effects. Cysteamine 170-180 somatostatin Homo sapiens 144-156 1972871-5 1990 Inactivation of somatostatin by the addition of cysteamine partially suppressed the inhibitory effect of bombesin on glandular secretion. Cysteamine 48-58 somatostatin Homo sapiens 16-28 2900049-6 1988 Cysteamine (90 mg/kg) treatment given s.c. produced a 50% depletion of endogenous brain somatostatin-like peptide concentrations. Cysteamine 0-10 somatostatin Homo sapiens 88-100 1648719-6 1991 Biological studies on the effects of increased brain somatostatin showed a facilitation in learning behavioural tasks, while brain somatostatin depletion by cysteamine caused memory loss. Cysteamine 157-167 somatostatin Homo sapiens 131-143 3828820-0 1987 Cysteamine-induced depletion of central somatostatin-like immunoactivity: effects on behavior, learning, memory and brain neurochemistry. Cysteamine 0-10 somatostatin Homo sapiens 40-52 3828820-5 1987 Cysteamine in doses of 50 mg/kg and above depleted cortical somatostatin-like immunoactivity by approximately 50%. Cysteamine 0-10 somatostatin Homo sapiens 60-72 3828820-7 1987 In addition to the depletion of somatostatin-like immunoactivity, high doses of cysteamine (150 mg/kg and above) produced changes in cortical levels of norepinephrine and dopamine, reminiscent of dopamine-beta-hydroxylase inhibition. Cysteamine 80-90 somatostatin Homo sapiens 32-44 3828820-9 1987 It is possible that the amnesia produced by cysteamine may have been due to the release of somatostatin into CSF from tissue stores, rather than somatostatin depletion per se. Cysteamine 44-54 somatostatin Homo sapiens 91-103 2874527-2 1986 A controlled therapeutic trial of the somatostatin-depleting agent, cysteamine, was therefore conducted in five patients, including one with the rigid-akinetic form. Cysteamine 68-78 somatostatin Homo sapiens 38-50 2863933-2 1985 Cysteamine-induced depletion of brain somatostatin-related peptides or central administration of a somatostatin receptor antagonist alters adrenomedullary epinephrine secretion and thermoregulation in a predictable manner. Cysteamine 0-10 somatostatin Homo sapiens 38-50 2874568-1 1986 The effects of prior treatment with cysteamine, a drug which appears to deplete selectively the neuropeptide somatostatin, on apomorphine-induced stereotypy and amphetamine-induced locomotor activity and conditioned place preferences were investigated. Cysteamine 36-46 somatostatin Homo sapiens 109-121 2874568-2 1986 Twelve hours following systemic cysteamine injections apomorphine-induced stereotypy was attenuated and striatal somatostatin levels were reduced by half. Cysteamine 32-42 somatostatin Homo sapiens 113-125 2874568-4 1986 Direct injections of cysteamine into the nucleus accumbens also decreased the locomotor response to amphetamine, and produced a local reduction in somatostatin levels in the accumbens. Cysteamine 21-31 somatostatin Homo sapiens 147-159 2874568-7 1986 Furthermore, it is evident from these results that cysteamine is an important tool with which to study the central actions of somatostatin. Cysteamine 51-61 somatostatin Homo sapiens 126-138 2863933-2 1985 Cysteamine-induced depletion of brain somatostatin-related peptides or central administration of a somatostatin receptor antagonist alters adrenomedullary epinephrine secretion and thermoregulation in a predictable manner. Cysteamine 0-10 somatostatin Homo sapiens 99-111 2863933-3 1985 The actions of cysteamine and the somatostatin receptor antagonist are reversed by administration of somatostatins into the central nervous system, supporting the hypothesis that endogenous brain somatostatin-related peptides are involved in the regulation of adrenomedullary epinephrine secretion and thermoregulation. Cysteamine 15-25 somatostatin Homo sapiens 101-113 9329060-2 1997 Low concentrations of cysteamine selectively depletes somatostatin and has been used to investigate the role of endogenous somatostatin in lieu of an available selective receptor antagonist. Cysteamine 22-32 somatostatin Homo sapiens 123-135 9329060-2 1997 Low concentrations of cysteamine selectively depletes somatostatin and has been used to investigate the role of endogenous somatostatin in lieu of an available selective receptor antagonist. Cysteamine 22-32 somatostatin Homo sapiens 54-66